BACKGROUND: The aim was to evaluate platelet concentrates (PCs) prepared by the automated OrbiSac system, from pooled buffy coats (BCs) stored in a platelet (PLT) additive solution. STUDY DESIGN AND METHODS: Experiment 1 was a paired in vitro study of PCs (from six BCs), prepared by automated and manual procedures. Experiments 2 and 3 evaluated PCs from OrbiSac (from six BCs); Experiment 3 included selection of BCs based on donor data. Experiment 4 was a paired in vitro study of PCs (from six BCs) with an integrated white blood cell (WBC) filter and two different storage containers. Experiment 5 evaluated PCs (from six BCs) from the OrbiSac with an integrated WBC filter. Experiment 6 was similar to Experiment 5 with computer-selected pools of 5 BCs. The in vitro studies evaluated the effects of 7-day storage of PLTs regarding PLT metabolism and disintegration. RESULTS: Experiments 1 and 4 had similar in vitro results. In Experiment 2, PLT content was 370 x 10(9) +/- 70 x 10(9) per PC and recovery from BCs was 76 +/- 6 percent. In Experiment 3, the PLT content was 380 x 10(9) +/- 50 x 10(9) per PC and variation was reduced compared with randomly pooled BCs. In Experiment 5, increased PLT content was found (420 x 10(9) +/- 70 x 10(9) per PC and recovery from BCs of 80 +/- 5%). In Experiment 6, five rather than six BCs gave 340 x 10(9) +/- 60 x 10(9) PLTs per PC and recovery was 79 +/- 5 percent. CONCLUSION: These in vitro studies suggest that the OrbiSac technique is equivalent to the standard manual method regarding the PLT in vitro characteristics during storage for 7 days. The results of standardizing the PLT count in PCs by selecting the BCs pools on the basis of the blood donor PLT concentration were encouraging.
No takes yet. Share an insight, caveat, or question.
Larsson et al. (2005) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: